Effects of resveratrol, a grape polyphenol, on uterine contraction and Ca2+ mobilization in rats in vivo and in vitro

Shih Min Hsia, Kai Lee Wang, Paulus S. Wang

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Dysmenorrhea is directly related to elevate prostaglandin F (PGF) levels. In Western medicine, this condition is treated using nonsteroidal antiinflammatory drugs. Because nonsteroidal antiinflammatory drugs produce many side effects, Chinese medicinal therapy is considered as a feasible alternative for treating dysmenorrhea. Many special physiological components used in Chinese medicine, such as resveratrol, have been isolated and identified. Resveratrol has many physiological functions, such as antioxidation and anticarcinogenic effects. However, the relationship between uterine smooth muscle contraction and resveratrol remains unknown. Here, we studied the in vitro and in vivo effects of resveratrol on uterine smooth muscle contraction. The uterus was separated from a female Sprague Dawley rat, and uterine smooth muscle contraction activity was measured and recorded. The results demonstrated that 1) resveratrol treatment inhibited PGF-, oxytocin-, acetylcholine-, and carbacholinduced uterine contractions in rats; 2) resveratrol inhibited uterine contractions stimulated by the Ca2+ channel activator (Bay K 8644) and depolarization in response to high K + (KCl); 3) resveratrol inhibited PGF-induced increases in the [Ca2+]i in human uterine smooth muscle cells; 4) resveratrol could mimicCa2+ channel blockers to block Ca2+ influx through voltage-operated Ca2+ channels inthe plasma membrane; and 5) resveratrol inhibited PGF-induced uterine contractions in rats in vivo. Resveratrol inhibited uterine contractions induced by PGF and high K+ in a concentration-dependent manner in vitro; furthermore, it inhibited Ca2+-dependent uterine contractions. Thus, resveratrol consistently suppressed the increases in intracellular Ca2+ concentrations ([Ca2+]i) induced by PGF and high K+ concentrations. It can be assumed that resveratrol probably inhibited uterine contraction by blocking external Ca2+ influx, leading to decreased [Ca2+]i. Therefore, resveratrol can be considered as a feasible alternative therapeutic agent for dysmenorrhea.

Original languageEnglish
Pages (from-to)2090-2099
Number of pages10
JournalEndocrinology
Volume152
Issue number5
DOIs
Publication statusPublished - May 2011
Externally publishedYes

Fingerprint

Uterine Contraction
Vitis
Polyphenols
Dinoprost
Myometrium
Dysmenorrhea
Muscle Contraction
Smooth Muscle
resveratrol
In Vitro Techniques
Anti-Inflammatory Agents
Medicine
Anticarcinogenic Agents
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
Prostaglandins F
Oxytocin
Pharmaceutical Preparations
Acetylcholine
Uterus
Smooth Muscle Myocytes

ASJC Scopus subject areas

  • Endocrinology

Cite this

Effects of resveratrol, a grape polyphenol, on uterine contraction and Ca2+ mobilization in rats in vivo and in vitro. / Hsia, Shih Min; Wang, Kai Lee; Wang, Paulus S.

In: Endocrinology, Vol. 152, No. 5, 05.2011, p. 2090-2099.

Research output: Contribution to journalArticle

@article{3bfed0965ef64c62912b6bea85447fb3,
title = "Effects of resveratrol, a grape polyphenol, on uterine contraction and Ca2+ mobilization in rats in vivo and in vitro",
abstract = "Dysmenorrhea is directly related to elevate prostaglandin F (PGF) 2α levels. In Western medicine, this condition is treated using nonsteroidal antiinflammatory drugs. Because nonsteroidal antiinflammatory drugs produce many side effects, Chinese medicinal therapy is considered as a feasible alternative for treating dysmenorrhea. Many special physiological components used in Chinese medicine, such as resveratrol, have been isolated and identified. Resveratrol has many physiological functions, such as antioxidation and anticarcinogenic effects. However, the relationship between uterine smooth muscle contraction and resveratrol remains unknown. Here, we studied the in vitro and in vivo effects of resveratrol on uterine smooth muscle contraction. The uterus was separated from a female Sprague Dawley rat, and uterine smooth muscle contraction activity was measured and recorded. The results demonstrated that 1) resveratrol treatment inhibited PGF2α-, oxytocin-, acetylcholine-, and carbacholinduced uterine contractions in rats; 2) resveratrol inhibited uterine contractions stimulated by the Ca2+ channel activator (Bay K 8644) and depolarization in response to high K + (KCl); 3) resveratrol inhibited PGF2α-induced increases in the [Ca2+]i in human uterine smooth muscle cells; 4) resveratrol could mimicCa2+ channel blockers to block Ca2+ influx through voltage-operated Ca2+ channels inthe plasma membrane; and 5) resveratrol inhibited PGF2α-induced uterine contractions in rats in vivo. Resveratrol inhibited uterine contractions induced by PGF2α and high K+ in a concentration-dependent manner in vitro; furthermore, it inhibited Ca2+-dependent uterine contractions. Thus, resveratrol consistently suppressed the increases in intracellular Ca2+ concentrations ([Ca2+]i) induced by PGF2α and high K+ concentrations. It can be assumed that resveratrol probably inhibited uterine contraction by blocking external Ca2+ influx, leading to decreased [Ca2+]i. Therefore, resveratrol can be considered as a feasible alternative therapeutic agent for dysmenorrhea.",
author = "Hsia, {Shih Min} and Wang, {Kai Lee} and Wang, {Paulus S.}",
year = "2011",
month = "5",
doi = "10.1210/en.2010-1223",
language = "English",
volume = "152",
pages = "2090--2099",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Effects of resveratrol, a grape polyphenol, on uterine contraction and Ca2+ mobilization in rats in vivo and in vitro

AU - Hsia, Shih Min

AU - Wang, Kai Lee

AU - Wang, Paulus S.

PY - 2011/5

Y1 - 2011/5

N2 - Dysmenorrhea is directly related to elevate prostaglandin F (PGF) 2α levels. In Western medicine, this condition is treated using nonsteroidal antiinflammatory drugs. Because nonsteroidal antiinflammatory drugs produce many side effects, Chinese medicinal therapy is considered as a feasible alternative for treating dysmenorrhea. Many special physiological components used in Chinese medicine, such as resveratrol, have been isolated and identified. Resveratrol has many physiological functions, such as antioxidation and anticarcinogenic effects. However, the relationship between uterine smooth muscle contraction and resveratrol remains unknown. Here, we studied the in vitro and in vivo effects of resveratrol on uterine smooth muscle contraction. The uterus was separated from a female Sprague Dawley rat, and uterine smooth muscle contraction activity was measured and recorded. The results demonstrated that 1) resveratrol treatment inhibited PGF2α-, oxytocin-, acetylcholine-, and carbacholinduced uterine contractions in rats; 2) resveratrol inhibited uterine contractions stimulated by the Ca2+ channel activator (Bay K 8644) and depolarization in response to high K + (KCl); 3) resveratrol inhibited PGF2α-induced increases in the [Ca2+]i in human uterine smooth muscle cells; 4) resveratrol could mimicCa2+ channel blockers to block Ca2+ influx through voltage-operated Ca2+ channels inthe plasma membrane; and 5) resveratrol inhibited PGF2α-induced uterine contractions in rats in vivo. Resveratrol inhibited uterine contractions induced by PGF2α and high K+ in a concentration-dependent manner in vitro; furthermore, it inhibited Ca2+-dependent uterine contractions. Thus, resveratrol consistently suppressed the increases in intracellular Ca2+ concentrations ([Ca2+]i) induced by PGF2α and high K+ concentrations. It can be assumed that resveratrol probably inhibited uterine contraction by blocking external Ca2+ influx, leading to decreased [Ca2+]i. Therefore, resveratrol can be considered as a feasible alternative therapeutic agent for dysmenorrhea.

AB - Dysmenorrhea is directly related to elevate prostaglandin F (PGF) 2α levels. In Western medicine, this condition is treated using nonsteroidal antiinflammatory drugs. Because nonsteroidal antiinflammatory drugs produce many side effects, Chinese medicinal therapy is considered as a feasible alternative for treating dysmenorrhea. Many special physiological components used in Chinese medicine, such as resveratrol, have been isolated and identified. Resveratrol has many physiological functions, such as antioxidation and anticarcinogenic effects. However, the relationship between uterine smooth muscle contraction and resveratrol remains unknown. Here, we studied the in vitro and in vivo effects of resveratrol on uterine smooth muscle contraction. The uterus was separated from a female Sprague Dawley rat, and uterine smooth muscle contraction activity was measured and recorded. The results demonstrated that 1) resveratrol treatment inhibited PGF2α-, oxytocin-, acetylcholine-, and carbacholinduced uterine contractions in rats; 2) resveratrol inhibited uterine contractions stimulated by the Ca2+ channel activator (Bay K 8644) and depolarization in response to high K + (KCl); 3) resveratrol inhibited PGF2α-induced increases in the [Ca2+]i in human uterine smooth muscle cells; 4) resveratrol could mimicCa2+ channel blockers to block Ca2+ influx through voltage-operated Ca2+ channels inthe plasma membrane; and 5) resveratrol inhibited PGF2α-induced uterine contractions in rats in vivo. Resveratrol inhibited uterine contractions induced by PGF2α and high K+ in a concentration-dependent manner in vitro; furthermore, it inhibited Ca2+-dependent uterine contractions. Thus, resveratrol consistently suppressed the increases in intracellular Ca2+ concentrations ([Ca2+]i) induced by PGF2α and high K+ concentrations. It can be assumed that resveratrol probably inhibited uterine contraction by blocking external Ca2+ influx, leading to decreased [Ca2+]i. Therefore, resveratrol can be considered as a feasible alternative therapeutic agent for dysmenorrhea.

UR - http://www.scopus.com/inward/record.url?scp=79955431007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955431007&partnerID=8YFLogxK

U2 - 10.1210/en.2010-1223

DO - 10.1210/en.2010-1223

M3 - Article

C2 - 21363935

AN - SCOPUS:79955431007

VL - 152

SP - 2090

EP - 2099

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 5

ER -